Targeting a specific gene to improve treatment for pancreatic cancer
Targeting GCNT3 for Pancreatic Cancer
This study is looking at how a gene called GCNT3 affects pancreatic cancer and is testing a new treatment that might help existing chemotherapy work better, which could lead to improved outcomes for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oklahoma City VA Medical Center NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project ID | NIH-10948921 on NIH RePORTER |
What this research studies
This research investigates the role of the GCNT3 gene in pancreatic cancer, which is known for its high mortality rate and low survival rates. The study aims to understand how GCNT3 contributes to cancer growth and resistance to treatment. By using advanced molecular techniques, researchers are exploring a novel inhibitor, talniflumate, that may effectively target GCNT3 and enhance the effectiveness of existing chemotherapy drugs. Patients may benefit from new treatment strategies that improve drug responsiveness and potentially increase survival rates.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic cancer, particularly those who have not responded well to standard treatments.
Not a fit: Patients with early-stage pancreatic cancer or those who have not been diagnosed with the disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, improving survival rates and quality of life for patients.
How similar studies have performed: While targeting specific genes in cancer treatment is a growing field, this particular approach focusing on GCNT3 is relatively novel and has not been extensively tested in previous studies.
Where this research is happening
Oklahoma City, United States
- Oklahoma City VA Medical Center — Oklahoma City, United States (Active)
Researchers
- Principal investigator: Rao, Chinthalapally V. — Oklahoma City VA Medical Center
- Study coordinator: Rao, Chinthalapally V.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.